Interstitial cell autophagy

Autophagy is an evolutionarily conserved lysosome-dependent catabolic pathway responsible for degrading unnecessary or dysfunctional cytoplasmic components through formation and maturation of double-membrane vesicles called autophagosomes. In interstitial cells—such as fibroblasts found within organ stroma—autophagic processes play essential roles under both physiological conditions by maintaining tissue architecture/homeostasis and under pathological conditions by contributing to disease mechanisms such as fibrosis. Aberrant activation can drive myofibroblast differentiation, extracellular matrix deposition, inflammation, G2/M arrest, epithelial-to-mesenchymal transition, and ultimately fibrotic progression especially notable in organs like kidney during chronic injury states[1][2][4]. While pharmacological modulation has been explored using agents that affect core regulatory nodes such as mTORC1/PI3K/Akt pathways or lysosomal function, these interventions impact global cellular processes rather than selectively targeting "interstitial cell autophagy" per se. In summary: "Interstitial cell autophagy" describes an important biological phenomenon/process relevant mainly in fibrotic disease research but does not represent an individual molecular target suitable for direct drug development efforts without further specification at the gene/protein level.

Other names

Autophagic flux in interstitial cellsStromal cell autophagyFibroblast autophagy (in some contexts)

Drugs modulate upstream regulators or effectors involved in the initiation or inhibition of the overall cellular process: mTOR inhibition induces macroautophagic flux. Lysosomal inhibitors block degradation phase. PI3K/Akt pathway modulation affects initiation.